• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Lincoln Alternative Strategies Llc claimed ownership of 730,000 shares (SEC Form 3)

    8/27/25 9:14:05 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CLDI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Lincoln Alternative Strategies LLC

    (Last) (First) (Middle)
    404 WASHINGTON AVE., SUITE 650

    (Street)
    MIAMI BEACH FL 33139

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/20/2025
    3. Issuer Name and Ticker or Trading Symbol
    Calidi Biotherapeutics, Inc. [ CLDI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.0001 per share 730,000 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Stephen Temes 08/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CLDI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLDI

    DatePrice TargetRatingAnalyst
    11/22/2023$11.00Buy
    H.C. Wainwright
    10/9/2023$9.00Outperform
    Robert W. Baird
    More analyst ratings

    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sanders Corazon (Corsee) D.

    3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    6/29/26 5:12:57 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Camaisa Allan sold $1,237 worth of shares (850 units at $1.46) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    12/16/25 7:37:06 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Poma Eric E

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    9/5/25 7:56:29 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    SEC Filings

    View All

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    7/16/26 5:30:30 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    6/23/26 8:30:46 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    6/18/26 5:00:32 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

    11/22/23 7:15:52 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

    Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

    10/9/23 7:23:07 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

    Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1 2027  Company demonstrated the versatility of the RedTail platform with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifiers. The Company is also advancing its EpCam-targeted In Situ TCE program. In Situ TCEs represent an important advancement of the RedTail platform Strengthened Board of Directors with addition of Corsee Sanders, Ph.D., former executive of Genentech/Roche and CelgeneComp

    7/21/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

    SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the "Reverse Stock Split"). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 under the existing symbol of "CLDI." The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 507. The decision to implement this stock split reflects the Company’s ai

    7/20/26 4:30:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company’s common stock on July 6, 2026, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stock Options vesting on the one

    7/8/26 4:05:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jackson Andrew C. bought $5,000 worth of shares (2,500 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:36 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Poma Eric E bought $50,000 worth of shares (25,000 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:39 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Leftwich Scott bought $250,000 worth of shares (125,000 units at $2.00), increasing direct ownership by 2,212% to 130,650 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:37 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Financials

    Live finance-specific insights

    View All

    Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

    Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026Presented new data on RedTail at the AACR conference in San Diego, CA detailing the use of the RedTail platform to create in vivo T-cell engagers that simultaneously express both a T-cell engager and a T-cell activator at high levels exclusively in the tumor microenvironment; presented new data on CLD-501, a TROP-2 in vivo T-cell engagerDemonstrated $1 million reduction in general and administrative expenses from Q1-2025 to Q1-2026Speaker presentation at ASGCT conference in Boston, MA highl

    5/14/26 4:10:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

    Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

    3/31/25 4:10:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

    SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    9/11/24 4:04:09 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company’s common stock on July 6, 2026, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stock Options vesting on the one

    7/8/26 4:05:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

    SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders has an exceptional track record in developing new technologies," said Calidi Chairman of the Board Jim Schoeneck. "We believe her deep expertise in the clinical development of novel therapeutics will be highly valuable as Calidi advances CLD-401 and its RedTail platform into

    6/23/26 8:00:00 AM ET
    $CLDI
    $LEGN
    $RARE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care